The Rohatyn Group Completes Sale of 36.6% Huvepharma Stake to Advance Properties

Advance Properties OOD total shareholding in Bulgarian pharmaceuticals company Huvepharma AD is now 100% November 20, 2014 07:00 AM Eastern Standard Time NEW YORK--(BUSINESS WIRE)--The Rohatyn Group ("TRG"), an independent investment firm focused on emerging markets, today announced that TRG Growth Fund II has finalised the sale of its 36.6% shareholding in Huvepharma AD to Advance Properties OOD, a company controlled by the Domuschiev family. Huvepharma AD, headquartered in Sofia, Bulgaria, is a global fully integrated pharmaceutical company focused on developing, manufacturing and marketing animal health and nutrition products, as well as several key ingredients used in human health products. As a result of this transaction, Advance Properties OOD effectively controls 100% of Huvepharma AD. Kiril Domuschiev, President of Huvepharma, stated: "TRG has been a strong partner for Huvepharma and we are pleased with their contribution to the rapid international development and growth of the company. We are excited that Advance Properties again holds a 100% controlling interest of Huvepharma and continues to support the company in the pursuit of further growth strategies. The combination of an experienced management team and staff and continued investment in product development and global production facilities gives us full confidence that Huvepharma is well placed to sustain an ambitious growth path." Sobhi Hatem, Managing Director of TRG, stated: "We are very proud of the successful investment in Huvepharma, which allowed TRG Growth Fund II to capitalise on the growth of one of the most attractive segments of the pharmaceuticals market. The growth that the company has achieved during our partnership period is a testament to our strong collaboration with Advance Properties, particularly with respect to the maximization of our complimentary international footprints. We are confident that the high quality management team that leads Huvepharma will continue to drive future success." TRG, along with its subsidiaries and affiliates, has over $5 billion in private emerging markets assets under management, in addition to almost $1 billion in liquid emerging market strategies. TRG last year acquired Citi Venture Capital International ("CVCI"), the emerging market private equity investment unit formerly owned by Citigroup Inc., which expanded and enhanced the firm's emerging markets investment capabilities and global reach. Huvepharma AD, which was founded in 2000 by the Domuschiev family, has worldwide operations with 99% of its production sold outside of Bulgaria in more than 95 countries. Huvepharma's key product categories are feed additives and veterinary products for food producing animals and active human pharmaceutical ingredients. For more information, please visit www.huvepharma.com. About Advance Properties OOD Advance Properties OOD is an investment holding company founded and controlled by Bulgarian entrepreneurs Kiril and Georgi Domuschiev. The company owns strategic shares in a well diversified portfolio of companies. In addition to Huvepharma AD, Advance Properties' investments include a 70% stake in Navigation Maritime Bulgare (Navibulgar), a Bulgarian shipping company, and other companies in the port operations services, real estate, logistics and manufacturing industries. The financial strength and flexibility of Advance Properties OOD's structure is reflected in its ability to provide strategic advice and enhance the effectiveness of management processes and the development of new markets, technologies and products across investments. The investee companies share a strong commitment to integrity, product quality and customer satisfaction. About TRG Founded in 2002, The Rohatyn Group is a leading emerging markets asset management firm headquartered in New York, with offices around the globe including, Singapore, Hong Kong, London, Buenos Aires, Lima, Montevideo, Mexico City, São Paulo, Mumbai and New Delhi. For more information, please visit www.rohatyngroup.com. Contacts Media For TRG: Paul Caminiti/Chris Kittredge/Brian Shiver, 212-687-8080 Sard Verbinnen & Co or For Advance Properties OOD: Yavor Iliev, +359 2 8625331

Suggested Articles

Pfizer spinoff Zoetis met Q2 expectations and brightened its full-year forecast, but it's looking to M&A to drive further growth.

Fresenius’ new CEO has pulled off a dealmaking double play, committing more than $5.4 billion to expand its reach in both sterile generics and in biosimilars.

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…